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Abstract:  18 
Reduced protein homeostasis leading to increased protein instability is a common molecular feature of 19 
aging, but it remains unclear whether this is a cause or consequence of the aging process. In 20 
neurodegenerative diseases and other amyloidoses, specific proteins self-assemble into amyloid fibrils 21 
and accumulate as pathological aggregates in different tissues. More recently, widespread protein 22 
aggregation has been described during normal aging. Until now, an extensive characterization of the 23 
nature of age-dependent protein aggregation has been lacking. Here, we show that age-dependent 24 
aggregates are rapidly formed by newly synthesized proteins and have an amyloid-like structure 25 
resembling that of protein aggregates observed in disease. We then demonstrate that age-dependent 26 
protein aggregation accelerates the functional decline of different tissues in C. elegans. Together, these 27 
findings imply that amyloid-like aggregates contribute to the aging process and therefore could be 28 
important targets for strategies designed to maintain physiological functions in the late stages of life.  29 
 30 
 31 
Introduction: 32 
Aging is a gradual decline in physiological functions and organ integrity and indeed diminished physical 33 
capacity and cognitive functions are already apparent before midlife (Belsky et al., 2015). The aging 34 
process greatly enhances the risk for chronic diseases leading to long-term disabilities in the elderly 35 
population and often premature death (Kaeberlein, 2013). A better understanding of what drives aging 36 
and in particular functional decline holds the promise of identifying targets to maintain quality of life 37 
with old age. It is generally agreed that the ultimate root causes of aging occur at the molecular level 38 
(Kaeberlein, 2013). One of the most universal hallmarks of aging is increased protein instability (Golubev, 39 
Hanson, & Gladyshev, 2017; Gorisse et al., 2016). In young individuals, an efficient protein homeostasis 40 
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(proteostasis) network prevents the accumulation of damaged proteins. However, overwhelming 41 
evidence points to a collapse in the proteostasis network with age and consequently a decline in the 42 
ability to cope with protein physical and chemical instability (Taylor & Dillin, 2011). Still the role of 43 
protein instability in aging is unclear (Finch & Crimmins, 2016; Hekimi, Lapointe, & Wen, 2011).  44 
During aging, an important cause of protein instability is cumulative damage through non-enzymatic 45 
posttranslational modifications occurring through reactions with metabolites and reactive oxygen 46 
species (Golubev et al., 2017). Destabilizing mutations, transcriptional and translational inefficacy are 47 
also a significant source of protein instability (Nedialkova & Leidel, 2015; Vermulst et al., 2015). In a 48 
disease context, a specific form of protein instability, namely protein aggregation, is a common feature 49 
of amyloidoses and many neurodegenerative diseases. In these diseases, a specific protein converts from 50 
its native soluble conformation into an insoluble state by self-assembly into a cross-β sheet filamentous 51 
structure termed amyloid fibril. Amyloid fibrils accumulate as pathological deposits in a variety of 52 
different tissues. Although most proteins contain amyloid-promoting sequences and form amyloid fibrils 53 
in appropriate conditions in vitro (Chiti et al., 1999; Goldschmidt, Teng, Riek, & Eisenberg, 2010), there is 54 
little evidence for this disease-related conformational state in metazoa in the absence of disease. Global 55 
proteomic characterizations of age-dependent protein insolubility, a hallmark of disease-associated 56 
protein aggregation, have been carried out in wild-type C. elegans (David et al., 2010; Reis-Rodrigues et 57 
al., 2012; Walther et al., 2015). Several hundred proteins enriched in distinct structural and functional 58 
characteristics were identified that lose their native structure in aged animals and become highly-59 
insoluble in strong detergents (David et al., 2010; Lechler et al., 2017; Reis-Rodrigues et al., 2012). In vivo 60 
data demonstrate that these proteins accumulate in solid/immobile structures in aged animals. 61 
However, until now it is not known whether these age-dependent protein aggregates contain amyloid 62 
fibrils. Elucidating the structural nature of this novel type of protein instability would help to understand 63 
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the causes and consequences of protein aggregation during aging and to explain potential interactions 64 
with disease-aggregating proteins.  65 
Since the initial discovery in C. elegans, age-dependent protein aggregation has been demonstrated in 66 
different organs in mammals (Ayyadevara, Balasubramaniam, et al., 2016; Ayyadevara, Mercanti, et al., 67 
2016; Groh, Buhler, et al., 2017; Leeman et al., 2018; Tanase et al., 2016). Importantly, age-dependent 68 
protein aggregation is likely to be relevant in neurodegenerative processes. Indeed, the over-69 
representation of proteins prone to aggregate with age among proteins sequestered in Alzheimer’s 70 
disease inclusions of amyloid plaques and tau neurofibrillary tangles highlights a possible contribution to 71 
pathological processes (Ciryam, Tartaglia, Morimoto, Dobson, & Vendruscolo, 2013; David et al., 2010). 72 
Moreover, recent evidence shows that aggregates from wild-type aged mouse brains are a potent 73 
heterologous seed for amyloid-β (Aβ) aggregation (Groh, Buhler, et al., 2017). However, because of the 74 
difficulties to distinguish the effects of protein aggregation from other consequences of aging, it is still 75 
not clear whether age-dependent protein aggregation plays a role in accelerating the aging process 76 
(David, 2012). A previous study has shown that C. elegans treated with RNAi targeting genes encoding 77 
aggregation-prone proteins tend to live longer than randomly chosen targets (Reis-Rodrigues et al., 78 
2012). However, the interpretation of these results is complicated by the loss-of-function of these 79 
proteins. Recently, we found that aged animals with high aggregation levels of an RNA-binding protein 80 
(RBP) with a low-complexity prion-like domain were shorter lived, significantly smaller and less motile 81 
than animals with low RBP aggregation levels (Lechler et al., 2017). Still this evidence does not provide a 82 
definite answer to whether age-dependent protein aggregation plays a causal role in aging rather than 83 
being a simple by-product. To understand whether protein aggregation is protective or harmful, it is 84 
informative to look at how long-lived animals modulate protein solubility. Longevity mechanisms and 85 
enhanced proteostasis are tightly coupled (Taylor & Dillin, 2011). However, whereas several studies 86 
show reduced age-dependent protein aggregation in long-lived animals (David et al., 2010; Demontis & 87 
5 
 
Perrimon, 2010; Lechler et al., 2017), a recent study suggests that enhancing protein aggregation could 88 
be a strategy to promote longevity (Walther et al., 2015).  89 
In the current study, we use a combination of transmission electron microscopy (TEM), fluorescence 90 
lifetime imaging (FLIM) (Kaminski Schierle et al., 2011), Thioflavin T (ThT) staining and structured 91 
illumination microscopy (SIM) (Young, Strohl, & Kaminski, 2016) to reveal amyloid-like structures in age-92 
dependent protein aggregates in vivo. Unlike protein chemical instability caused by cumulative damage, 93 
age-dependent protein aggregates are formed by intrinsically aggregation-prone proteins, even shortly 94 
after their synthesis. We demonstrate that age-dependent protein aggregation is toxic and contributes 95 
to functional decline in C. elegans.  96 
 97 
Results: 98 
Age-dependent aggregating proteins are intrinsically prone to aggregate in certain tissues. 99 
Previously, we performed an extensive characterization of the aggregation of two proteins, casein kinase 100 
I isoform alpha (KIN-19) and Ras-like GTP-binding protein rhoA (RHO-1). Both KIN-19 and RHO-1 were 101 
identified among the proteins with the highest propensity to become insoluble with age in wild-type C. 102 
elegans somatic tissues (David et al., 2010). In vivo analysis of animals expressing these proteins fused to 103 
fluorescent tags showed the appearance of immobile deposits with age (David et al., 2010). Among the 104 
insoluble proteome, the enrichment of certain physico-chemical features such as high aliphatic amino 105 
acid content or propensity to form β-sheet-rich structures shows that age-dependent protein 106 
aggregation is not random (David et al., 2010; Lechler et al., 2017; Walther et al., 2015). To understand 107 
whether KIN-19 and RHO-1 have an intrinsic capacity to aggregate similar to disease-associated proteins 108 
or whether a progressive accumulation of protein damage caused by non-enzymatic posttranslational 109 
modifications is required to induce their aggregation, we evaluated the dynamics of protein aggregation 110 
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in vivo. Protein labeling with mEOS2, a green-to-red photoconvertible fluorescent protein, has been 111 
successfully used to track protein dynamics (McKinney, Murphy, Hazelwood, Davidson, & Looger, 2009). 112 
In the present case, we used the mEOS2 tag to investigate how fast newly synthesized KIN-19 and RHO-1 113 
aggregate. For this purpose, we generated transgenic animals expressing KIN-19::mEOS2 in either the 114 
pharynx or in the body-wall muscles and transgenic animals expressing RHO-1::mEOS2 in the pharynx. 115 
The mEOS2 tag did not disrupt the aggregation potential of KIN-19, as the absence of fluorescence 116 
recovery after photobleaching confirms that both KIN-19::mEOS2 puncta in the pharynx and body-wall 117 
muscle are highly immobile structures (Figure supplement 1 A-D).  118 
To follow newly synthesized proteins, we set-up a system to perform irreversible photoconversion of the 119 
mEOS2 tag present in live animals from green to red by exposing them to intense blue light. At a defined 120 
time-point, we photoconverted the mEOS present in aggregates to red. After the photoconversion, 121 
newly synthesized proteins emitted green fluorescence and could thus easily be distinguished from old 122 
(photoconverted/red) aggregates. This method allowed us to follow the rate of new aggregate formation 123 
and the rate of old aggregate removal in a population of transgenic animals over time. We observed 124 
photoconversion of all aggregates, but we also noted that the core region of some larger aggregates 125 
continued to emit green fluorescence (Figure 1 A, B). Interestingly, we observed a doubling in the 126 
number of animals with newly-formed green aggregates, 24 hours after the conversion at day 5 of 127 
adulthood in both the pharyngeal and body-wall muscles. Conversely, analysis of the red aggregates 128 
suggested a slow removal of old aggregates (Figure 1 A, B, Supplementary file 1). Blocking translation 129 
shortly before conversion reduced the formation of new aggregates (Figure 1 B). Conversion in young 130 
animals and blocking translation produced similar results (Figure supplement 1 E). Confocal imaging 131 
shows that newly synthesized KIN-19 associate with pre-existing aggregates (Figure 1 C). However, we 132 
also observed large aggregates emitting only green fluorescence suggesting that seeding is not a 133 
prerequisite for KIN-19 aggregate formation (Figure 1 C). We observed similar aggregation kinetics in 134 
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animals with RHO-1::mEOS2 expressed in the pharynx (Figure supplement 1 F). Together, these results 135 
reveal that aggregate formation can proceed rapidly after protein synthesis.  136 
 137 
Age-dependent protein aggregates contain amyloid-like structures in vivo. 138 
Both KIN-19 and RHO-1 are nearly identical to their human orthologues (sequence identity over 87%). X-139 
ray diffraction shows that the human orthologues are globular proteins formed by a series of α-helices 140 
and β-strands. The ability of KIN-19 and RHO-1 to aggregate shortly after synthesis suggests that their 141 
aggregation may be associated with the presence of folding intermediates. Notably, both proteins have 142 
several segments with a high amyloid propensity (Figure supplement 2 A, B) (Goldschmidt et al., 2010). 143 
This feature raises the possibility that KIN-19 and RHO-1 gain an amyloid-like conformation during their 144 
aggregation with age. We have previously shown that FLIM can be used to determine whether certain 145 
proteins are likely to form amyloid-like aggregates as the formation of amyloid fibrils leads to a 146 
significant drop in the fluorescence lifetime of the fluorescent-tagged amyloid proteins due to quenching 147 
(Chen et al., 2017; Kaminski Schierle et al., 2011; Murakami et al., 2015). In the current study, we applied 148 
FLIM to determine whether KIN-19 and RHO-1 form amyloid-like aggregates in live C. elegans. For this, 149 
we generated transgenic animals expressing translational fusions with the yellow fluorescent protein 150 
Venus in the pharynx. We first confirmed that there is an age-dependent increase in aggregate formation 151 
by KIN-19::Venus and RHO-1::Venus in the pharynx (Figure supplement 3 A, B) (Lechler et al., 2017). 152 
Using FLIM, we found that pharyngeal KIN-19 and RHO-1::Venus display a significantly decreased 153 
fluorescence lifetime compared to Venus only control worms (Figure 2 A-C, Figure supplement 4 A). 154 
Areas with the strongest drop in fluorescence lifetime co-localize with fluorescent-labeled aggregates 155 
(Figure 2 A). Of note, we also observed a similar drop in the fluorescence lifetime of pharyngeal RHO-1 156 
labeled with tagRFP compared to tagRFP alone (Figure supplementary 4 B). In both models with KIN-19 157 
and RHO-1, we observed a significant drop in the fluorescence lifetime already at day 1, consistent with 158 
8 
 
the appearance of aggregates in young animals due to protein overexpression. In particular, between 159 
day 1 and day 7 of adulthood, we measured a dramatic decrease in fluorescence lifetime of RHO-1 160 
aggregates and a more modest decrease in the fluorescence lifetime of KIN-19 aggregates. This result is 161 
consistent with the age-dependent increase in aggregate formation by both proteins and the fact that 162 
RHO-1 puncta tend to be larger and more solid than KIN-19 puncta. Indeed, all RHO-1 puncta evaluated 163 
showed no recovery after photobleaching whereas 30% of KIN-19 puncta showed some recovery as 164 
previously described (Figure supplement 3 C-E compared to (David et al., 2010)). In addition to 165 
evaluating the fluorescence lifetime, we assessed whether RHO-1 aggregates are stained by the Congo 166 
red derivative X34 previously used to detect amyloid deposits (Styren, Hamilton, Styren, & Klunk, 2000). 167 
Consistent with the amyloid-like nature of the aggregates, we observed co-localization of X34 with RHO-168 
1 aggregates in vivo (Figure supplementary 4C-E). 169 
To gain more insight into the capacity of RHO-1 to form amyloid-like fibrils, we expressed and purified 170 
recombinant RHO-1 (Figure supplement 5 A, B) and aggregated it over time by constant shaking in 171 
stabilizing buffer to induce fibrillisation at 37˚C for a week. We obtained low quantities of RHO-1 fibrils, 172 
which we were able to analyze by TEM. Analysis of RHO-1 by TEM revealed fibril-like structures which 173 
resemble amyloid fibrils such as formed by huntingtin (Htt) (Figure supplement 5 C) (Reif, Chiki, Ricci, & 174 
Lashuel, 2018). Indeed, RHO-1 fibrils had a morphology more similar to Htt fibrils which are shorter and 175 
more branch-like compared to fibrils formed from other amyloids such as alpha-synuclein, which are 176 
long and flexible. Additionally, RHO-1 and Htt fibrils display no twisting which can be observed in alpha-177 
synuclein fibrils, suggesting that the packing of the monomeric structure and the interaction between 178 
protofibrils may be different (Lyubchenko, Krasnoslobodtsev, & Luca, 2012). Importantly, already at day 179 
1, we found comparable fibrillary structures in extracts from RHO-1::Venus transgenic animals (Figure 180 
supplement 5 D). In order to confirm that similar fibril structures can be found in the absence of a 181 
fluorescent tag, we have isolated fibrils by affinity purification from day 7 old transgenic worms 182 
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expressing pharyngeal RHO-1::HisAvi and KIN-19::HisAvi and imaged them by TEM (Figure supplement 183 
5E). Moreover, we have stained isolated RHO-1::HisAvi day 7 fibrils, RHO-1::tagRFP day 2 fibrils and 184 
extracts from non-aggregated control worms day 2 with amyloid-binding molecule ThT. Using SIM, we 185 
found ThT positive RHO-1 fibrils as shown previously for polyglutamine and Aß fibrils in cells (Lu et al., 186 
2019; Young et al., 2016) (Figure supplement 6). 187 
Together, these findings strongly suggest that Casein kinase I isoform alpha and Ras-like GTP-binding 188 
protein rhoA aggregates contain amyloid-like structures in vivo.  189 
 190 
Age-dependent protein aggregation accelerates functional decline. 191 
A reliable indicator of human aging is a decline in physical capacity such as decreased muscle strength 192 
and coordination (Belsky et al., 2015). Similarly, C. elegans displays an age-related decline in pharyngeal 193 
pumping and body movement (Huang, Xiong, & Kornfeld, 2004). To investigate whether age-dependent 194 
protein aggregation accelerates functional decline with age, we measured pharyngeal pumping and 195 
swimming in liquid (thrashing) in transgenic animals overexpressing fluorescent-labeled KIN-19 and RHO-196 
1 either in the pharynx or the body-wall muscles. In all models, protein aggregation increased with age, 197 
as measured by the change from a diffuse distribution to the formation of specific puncta by the 198 
fluorescent-tagged proteins (Figure supplement 7). Among the transgenic models generated, the largest 199 
age-dependent changes were observed for C. elegans expressing KIN-19::tagRFP in the pharynx (Figure 200 
supplement 7 A, E) (David et al., 2010). Whereas the majority of these transgenic animals have no 201 
aggregation at day 2, this dramatically changes with age and at day 8, the majority display high levels of 202 
KIN-19::tagRFP aggregation. Importantly, pumping frequency was strongly reduced in day 7 aged animals 203 
with the highest levels of pharyngeal KIN-19::tagRFP aggregation compared to those with the lowest 204 
aggregation levels (Figure 3 A, Supplementary file 2). The detrimental effect of age-dependent protein 205 
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aggregation was also apparent in animals with KIN-19::tagRFP aggregation in the body-wall muscles, 206 
since we observed an earlier decline in swimming frequency associated with KIN-19::tagRFP aggregation 207 
in the body-wall muscle (Figure supplement 8 A). This effect was amplified in animals with the highest 208 
level of aggregation (Figure 3 B). Of note, the fluorescent tagRFP expressed alone in the pharynx or in the 209 
body-wall muscle did not affect muscle function (Figure supplement 8 A, C).  Decreased body movement 210 
with age is associated with increased sarcopenia characterized by disordered sarcomeres and reduced F-211 
actin filaments (F-actin) (Baird et al., 2014; Herndon et al., 2002). To evaluate whether the presence of 212 
KIN-19 aggregates is linked to muscle damage at the cellular level, we assessed F-actin staining in animals 213 
with KIN-19 aggregation in the body-wall muscles. We found that animals with aggregates tended to 214 
have higher levels of disrupted sarcomers compared to controls (Figure supplement 9 A, B).  215 
 216 
To further show that protein aggregation is the cause of the functional decline in our transgenic animal 217 
models rather than other co-occurring aging factors, we examined the effects of protein aggregation in 218 
the absence of aging. Most likely due to the high level of overexpression in the pharyngeal muscles, RHO-219 
1::tagRFP aggregated abundantly already in young animals (Figure supplement 7 C, E). We found that 220 
these high levels of RHO-1::tagRFP aggregation strongly impaired pharyngeal pumping in young animals 221 
(day 2) (Figure 3 C). Notably, these young animals displayed pumping rates normally observed only in 222 
aged animals. Moreover, RHO-1 aggregation disrupted actin filament structure in the pharyngeal 223 
muscles (Figure supplement 9C, D). To exclude that RHO-1 overexpression itself is toxic to C. elegans, we 224 
examined another transgenic model where RHO-1::Venus is expressed under the strong C. elegans body-225 
wall muscle promoter Punc-54. These animals have similar levels of transgene expression compared to 226 
animals with body-wall muscle KIN-19::tagRFP (Figure supplement 7 F). Yet, whereas KIN-19 aggregates 227 
abundantly in the body-wall muscle, RHO-1::Venus hardly aggregates in this tissue (Figure supplement 7 228 
D). Thus, these transgenics are a suitable control to identify RHO-1 toxicity caused by overexpression. 229 
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Importantly, we did not observe reduced thrashing in animals with body-wall muscle RHO-1, 230 
demonstrating that overexpressed of RHO-1 without concomittant aggregation is not toxic (Figure 3 D). 231 
Similarly, the observation that only animals with the highest levels of pharyngeal KIN-19::tagRFP 232 
aggregation have functional impairment shows that KIN-19::tagRFP overexpression alone does not cause 233 
pumping defects (Figure 3 A and Figure supplement 8 B). Together, these positive and negative controls 234 
reveal that protein aggregation itself is detrimental in C. elegans. 235 
Collectively, these findings show that animals with accelerated protein aggregation experience an earlier 236 
onset of functional decline in the tissues affected.  237 
 238 
Discussion: 239 
Widespread protein aggregation in the context of normal aging has been observed in C. elegans (David et 240 
al., 2010; Reis-Rodrigues et al., 2012; Walther et al., 2015), Drosophila (Demontis & Perrimon, 2010), 241 
Saccharomyces cerevisiae (Peters et al., 2012) and in mammals, notably in neural stem cells (Leeman et 242 
al., 2018), heart (Ayyadevara, Mercanti, et al., 2016) and skeletal muscles (Ayyadevara, 243 
Balasubramaniam, et al., 2016), bone marrow and spleen (Tanase et al., 2016).  Whereas these hundreds 244 
of proteins are maintained in a functional and soluble state in young animals, they lose their functional 245 
structure with age and accumulate into insoluble aggregates. The detergent insoluble properties and 246 
solid nature of the aggregates indicate similarities with disease-associated protein aggregation. However, 247 
until now it has not been known whether age-dependent protein aggregates display amyloid-like 248 
structures, a key characteristic of disease-associated protein aggregation. In this study, we focus on two 249 
normally globular proteins, Casein kinase I isoform alpha and Ras-like GTP-binding protein rhoA. We 250 
show that aggregates of either proteins display distinct fluorescence quenching properties characteristic 251 
of amyloid structures. In neurodegenerative diseases and amyloidosis, protein aggregation is a crucial 252 
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part of the pathological process. We demonstrate that aggregates formed by proteins prone to 253 
aggregation with age contribute to functional decline in the tissues affected. Our results predict that 254 
even if only a proportion of the hundreds of proteins becoming insoluble with age form harmful amyloid-255 
like aggregates, this would be a significant cause of tissue aging for a variety of organs. 256 
The speed of aggregate formation and the presence of amyloid-like structure brings significant insight 257 
into the aggregation process occurring during normal aging. We demonstrate that newly synthesized 258 
proteins rapidly assemble into large aggregates. The recruitment of newly synthesized proteins into 259 
existing aggregates indicates a seeding effect. However, we also observed the rapid formation of new 260 
aggregates entirely made up of newly synthesized proteins. This result shows that molecular aging of the 261 
protein caused by progressive accumulation of damage is not required for proteins to aggregate with 262 
age. Moreover, amyloid-like aggregates forming already in young animals indicate an intrinsic 263 
aggregation propensity. Therefore, it is likely that these proteins self-assemble into amyloid structures 264 
directly from unfolded or partially folded states occurring during or shortly after translation rather than 265 
undergoing unfolding from their natively folded state. This conclusion is consistent with the view that 266 
protein folding intermediates are particularly at risk of aggregating as exemplified by a recent study 267 
revealing that newly synthesized proteins constitute the majority of the insoluble fraction prompted by 268 
thermal stress (Xu et al., 2016). Furthermore, artificially increasing ribosome pausing during translation 269 
causes widespread protein aggregation (Nedialkova & Leidel, 2015). Both Casein kinase I isoform alpha 270 
and Ras-like GTP-binding protein rhoA contain several hexapeptides with high propensity for fibrillation 271 
which are normally buried in the fully folded protein (Figure supplement 2). Interestingly, the most 272 
prominent amyloid-promoting sequence for both proteins is localized near the N-terminus. Therefore, 273 
aberrant interactions may start already during translation. As protein aggregation typically results in loss 274 
of function, there is a strong evolutionary pressure to avoid this and molecular chaperones have evolved 275 
to recognize specifically sequences of high aggregation propensity (Rousseau, Serrano, & Schymkowitz, 276 
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2006). Our findings predict that age-dependent protein aggregation would result from decreased levels 277 
of molecular chaperones linked to protein synthesis rather than molecular chaperones induced by stress 278 
(Albanese, Yam, Baughman, Parnot, & Frydman, 2006; Pechmann, Willmund, & Frydman, 2013). 279 
Impaired proteasome-mediated removal of unfolded proteins directly after synthesis (Schubert et al., 280 
2000) could also significantly contribute to age-dependent protein aggregation. Interestingly, the relative 281 
lack of Ras-like GTP-binding protein rhoA aggregation in the body-wall muscles compared to the 282 
pharyngeal muscles shows that this protein only aggregates within a specific cellular environment. Thus 283 
tissue-specific factors could be crucial for the aggregation process. These could be differences in the 284 
tissue proteostasis network and reliance on certain proteostasis components with age (Hamer, 285 
Matilainen, & Holmberg, 2010; Kern, Ackermann, Clement, Duerk, & Behl, 2010; Sala, Bott, & Morimoto, 286 
2017) but also age-related changes in the local tissue environment. For example, tissue-specific changes 287 
in ATP levels (Patel et al., 2017), availability of certain ions such as Ca2+ (Lautenschlager et al., 2018), 288 
redox state (Kirstein et al., 2015), could explain why certain proteins aggregate in one tissue but not 289 
another. 290 
The resemblance between age-dependent protein aggregation and disease-associated protein 291 
aggregation raises the question whether they have similar proteotoxic mechanisms. Our results show 292 
that there is a strong correlation between the presence of large aggregates and impaired tissue function. 293 
In disease, intracellular aggregate toxicity is caused, at least in part, by sequestration and the resulting 294 
loss of function of essential cellular proteins (Hosp et al., 2017; Olzscha et al., 2011; Yu et al., 2014). 295 
Notably, proteostasis network components are significantly enriched in the age-dependent insoluble 296 
proteome (David et al., 2010). Therefore loss-of-function of proteins responsible for preventing 297 
aggregation could be a key source of toxicity. The correlation between large aggregates and 298 
proteotoxicity observed in the present study, does not exclude that intermediate forms on the path to 299 
age-dependent protein aggregation are also proteotoxic. Indeed, disease-associated pre-fibrillar species 300 
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or oligomers can be highly toxic by interacting through their hydrophobic side chains with other cellular 301 
components and in particular lipid membranes (Fusco et al., 2017; Knowles, Vendruscolo, & Dobson, 302 
2014; Walsh et al., 2002). Further experiments will be needed to characterize which types of 303 
intermediate species occur during age-dependent protein aggregation and to evaluate their potential 304 
toxicity. Conversely, it remains possible that some forms of age-dependent protein aggregation could be 305 
protective or manipulated to form harmless non-amyloid aggregates. Finally, it is possible that age-306 
dependent protein aggregation occurring in one tissue will induce accelerated aging in another tissue. 307 
Following the evidence for seeding, self-propagation and cell-to-cell transfer of amyloid aggregating 308 
species in a disease context (Jucker & Walker, 2013), it is intriguing to speculate that the same 309 
mechanisms may arise with proteins aggregating during normal aging.  310 
The proteotoxicity and amyloid conformation of age-dependent protein aggregation has important 311 
implications for diseases associated with protein aggregation. Accelerated functional decline and the 312 
overload of the proteostasis network caused by age-dependent protein aggregation could indirectly 313 
enhance disease-associated pathogenesis. There is also evidence for a direct connection between 314 
disease and aging-related aggregation. Indeed, a significant proportion of the proteins sequestered in 315 
disease pathological deposits are prone to aggregate with age (Ciryam et al., 2013; David et al., 2010). 316 
Notably, Casein kinase I isoform alpha is present in tau aggregates (Kannanayakal, Mendell, & Kuret, 317 
2008; Kuret et al., 1997). Therefore, age-dependent aggregation-prone proteins interact with disease-318 
aggregating proteins in humans. Furthermore, we have demonstrated that minute amounts of insoluble 319 
proteins from aged wild-type mouse brains or aged C. elegans are sufficient to cross-seed amyloid-β 320 
aggregation in vitro (Groh, Buhler, et al., 2017). One possibility is that the highly hydrophobic nature of 321 
the amyloid-like structures in age-dependent protein aggregates provides a destabilizing surface that can 322 
promote the conformational conversion of disease-associated aggregating proteins. If the composition of 323 
the insoluble proteome is cell-specific, increases in age-dependent protein aggregation, for example 324 
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through higher expression or somatic aggregation-promoting mutations (Freer et al., 2016; Lodato et al., 325 
2018), could sensitize specific cells to disease-associated pathogenesis. 326 
In summary, our study demonstrates that aggregation of proteins during normal aging resembles 327 
pathological protein aggregation observed in neurodegenerative diseases and amyloidosis. We then 328 
show that age-dependent protein aggregation causes early functional decline, a read-out of accelerated 329 
aging. These findings emphasize age-dependent amyloid-like aggregation as an important target to 330 
restore physical capacity and to promote healthy aging. Already promising results reveal that lysosome 331 
activation in the germline and in aged neural stem cells clears protein aggregates and rejuvenates the 332 
cells (Bohnert & Kenyon, 2017; Leeman et al., 2018).    333 
 334 
Methods: 335 
Key Resources Table : 336 
Reagent 
type 
(species) 
or 
resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
Gene (C. 
elegans) 
kin-19 
Wormbase 
WBGene000022
02   
Gene (C. 
elegans) 
rho-1 
Wormbase 
WBGene000043
57   
Strain (E. 
coli) 
OP50-1 
Caenorhabditis 
genetic center 
(CGC) 
RRID:WB-
STRAIN:OP50-1 
Streptomycin 
resistant strain of 
OP50 
Genetic 
reagent (C. 
elegans) 
muEx473[Pkin-19::kin-
19::tagrfp + Ptph-1::gfp] 
doi: 
10.1371/journal.pbio
.1000450 
RRID:WB-
STRAIN:CF3166 N2 background 
Genetic 
reagent (C. 
elegans) 
muEx512[pkin-19::tagRFP 
+ Ptph-1::GFP] 
doi: 
10.1371/journal.pbio
.1000450 CF3317 N2 background 
Genetic 
reagent (C. 
elegans) 
 muIs209[Pmyo-3::kin-
19::tagrfp + Ptph-1::gfp] 
doi: 
10.1371/journal.pbio
.1000450 CF3649 N2 background 
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Genetic 
reagent (C. 
elegans) 
muIs210[pmyo-3::tagrfp + 
ptph-1::GFP] 
doi: 
10.1371/journal.pbio
.1000450 CF3650 N2 background 
Genetic 
reagent (C. 
elegans) 
muEx587[Pkin-19::kin-
19::meos2 + Punc-
122::gfp] this paper CF3706 N2 background 
Genetic 
reagent (C. 
elegans) 
uqIs9[Pmyo-2::rho-
1::tagrfp + Ptph-1::gfp] 
this paper DCD13 N2 background 
Genetic 
reagent (C. 
elegans) 
uqEx4[Pmyo-3::kin-
19::meos2] 
this paper DCD69 N2 background 
Genetic 
reagent (C. 
elegans) 
uqEx[Pmyo-2::rho-
1::meos2 + Punc-122::gfp 
+ cb-unc-119(+)] 
this paper DCD83 
injected into 
EG6699 
containing 
ttTi5605II; unc-
119(ed3)III 
Genetic 
reagent (C. 
elegans) 
uqEx22[Punc-54::rho-
1::venus] 
this paper DCD127 N2 background 
Genetic 
reagent (C. 
elegans) 
uqIs12[Pmyo-2::rho-
1::venus] 
this paper DCD146 N2 background 
Genetic 
reagent (C. 
elegans) 
uqEx37[Pkin-19::kin-
19::venus + punc-122::gfp] 
doi: 
10.1016/j.celrep.201
6.12.033 DCD179 N2 background 
Genetic 
reagent (C. 
elegans) 
uqIs22 
[pkin19::kin19::hisavi + 
pkin19::birAtagrfp] this paper DCD242 
fem-1(hc17ts)IV 
background 
Genetic 
reagent (C. 
elegans) 
uqIs19 
[pmyo2::rho1::hisavi + 
pmyo2::birAtagrfp] this paper DCD243 
fem-1(hc17ts)IV 
background 
Genetic 
reagent (C. 
elegans) 
uqEx49[pkin-19::meos] 
this paper DCD245 N2 background 
Genetic 
reagent (C. 
elegans) 
uqEx51[pmyo-2::venus] 
this paper DCD248 N2 background 
Genetic 
reagent (C. 
elegans) 
rmIs126[Punc-54::YFP] https://doi.org/10.10
73/pnas.152161099  
RRID:WB-
STRAIN:AM134 N2 background 
Genetic 
reagent (C. 
elegans) 
fem-1(hc17ts)IV 
CGC 
WB Cat# BA17, 
RRID:WB-
STRAIN:BA17   
recombina
nt DNA 
reagent 
tagRFP Evrogen, pTagRFP-
N, FP142     
recombina
nt DNA 
reagent 
pKA1062 containing 
mEOS2 
other   
Kaveh Ashrafi, 
UCSF, USA 
antibody Phalloidin-iFluor™ 488 
conjugate  
ABD-23115, AAT 
Bioquest, Biomol, 
Germany   "1:50" 
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chemical 
compound, 
drug X34 
SML1954, Sigma-
Aldrich, Germany   1mM final 
chemical 
compound, 
drug thioflavin T 
#ab120751, abcam, 
UK   50 µM  
commercial 
assay or kit 
5-Hydroxytryptamine 
creatinine sulfate complex  
H7752, Sigma-
Aldrich, Germany   10 µM 
commercial 
assay or kit 
Nickel Sepharose 6 Fast 
Flow beads  from HisTrap 
FF Crude column  
GE Healthcare, 
Uppsala, Sweden     
 337 
Cloning and Strain Generation: 338 
Cloning was carried out using the Gateway system (Life Technologies, Darmstadt, Germany). Pmyo-2 339 
promoter and pKA1062 mEOS2 translational vector were kindly provided by Dr. Brian Lee and Dr. Kaveh 340 
Ashrafi, UCSF.  rho-1 cDNA was amplified from a cDNA library prepared from total RNA isolated from N2 341 
worms. Plasmid containing biotinylation enzyme birA was kindly provided by Dr. Ekkehard Schulze 342 
(University Freiburg). All constructs contain the unc-54 3′ UTR. The tagrfp vector was obtained from 343 
Evrogen (AXXORA, San Diego, CA, USA). Venus was generated by targeted mutation of the yfp gene. 344 
HisAvi tagged KIN-19 and RHO-1 were generated by cloning at the C-terminus a RGSH6 tag together with 345 
a bacterially derived polypeptide serving as a biotinylation signal in vivo as previously described (Schaffer 346 
et al., 2010; Tagwerker et al., 2006). Constructs were sequenced at each step. Transgenics were 347 
generated by microinjection of the constructs at concentrations between 10 to 50 ng/µl into N2 animals. 348 
Stable lines were generated by irradiating the animals containing the extrachromosomal array in a CL-349 
1000 Ultraviolet Crosslinker (UVP) with 275µJ x 100. 100% transmission lines was backcrossed at least 350 
four times into the wild-type N2 strain. 351 
 352 
Maintenance: 353 
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All strains were kept at 15°C on NGM plates inoculated with OP50 using standard techniques. Age-354 
synchronization was achieved by transferring adults of the desired strain to 20°C and selecting their 355 
progeny at L4 stage. All experiments were performed at 20°C. Day 1 of adulthood starts 24h after L4. 356 
 357 
Photoconversion of mEOS2-tag and quantification of fluorescence levels: 358 
For photoconversion, worms were transferred onto a small (diameter 35 mm) NGM plate without food. 359 
The plate was placed 0.5 cm below a collimator (Collimator High-End Lumencor, Leica, Germany) fitted 360 
with a filter for blue fluorescence (387/11 BrightLine HC, diameter 40mm) and illuminated by a 361 
Lumencor Sola SE II (AHF, Tübingen). Conversion of mEOS2 in transgenic animals was performed four 362 
times for five minutes, with 2 minutes pauses between exposures. To reduce translation, worms were 363 
placed two hours before conversion on bacterial seeded plates with 500 µg/ml cycloheximide and kept 364 
after conversion on plates with cycloheximide for 48h during aggregation quantification.  365 
 366 
Aggregation quantification in vivo: 367 
Aggregation levels were determined using Leica fluorescence microscope M165 FC with a Planapo 2.0x 368 
objective. Aggregation was quantified following pre-set criteria adapted to the transgene expression 369 
pattern and levels in the different transgenic C. elegans models: Animals expressing Pkin-19::KIN-370 
19::mEOS2, Pkin-19::KIN-19::Venus or Pkin-19::KIN-19::TagRFP were divided into less than 10 puncta 371 
(low aggregation), between 10 and 100 puncta (medium aggregation) and over 100 puncta in the 372 
anterior pharyngeal bulb (high aggregation). Animals overexpressing Pmyo-2::RHO-1::Venus were 373 
divided into less than 10 puncta in anterior or posterior pharyngeal bulb (low aggregation),  over 10 374 
puncta in either bulbs (medium aggregation) and over 10 puncta in both bulbs (high aggregation). 375 
Because of extensive RHO-1 aggregation in animals overexpressing Pmyo-2::RHO-1::TagRFP, aggregation 376 
was only quantified in the isthmus: animals with no aggregation (low aggregation), animals with 377 
19 
 
aggregation in up to 50% (medium aggregation) and animals with aggregation in more than 50% (high 378 
aggregation) of the isthmus. Animals overexpressing Pmyo-3::KIN-19::TagRFP were divided into over 15 379 
puncta in the head or the middle body region (low aggregation), over 15 puncta in the head and the 380 
middle body region (medium aggregation) and over 15 puncta in head, middle body and tail region (high 381 
aggregation). The same categories defined for animals overexpressing Pmyo-3::KIN-19::TagRFP were 382 
used to evaluate animals overexpressing Pmyo-3::KIN-19::mEOS2 with a cutoff of 10 puncta instead of 15 383 
to account for slightly lower aggregation levels. Animals overexpressing Punc-54::RHO-1::Venus were 384 
divided into two categories:  less than 15 puncta in the whole animal (low aggregation) and over 15 385 
puncta in the whole animal (medium aggregation). Counting was done in a blind fashion. Two-tailed 386 
Fisher’s exact test using an online tool (https://www.socscistatistics.com/tests/fisher/default2.aspx) was 387 
performed for statistical analysis.  388 
 389 
Confocal imaging: 390 
For confocal analysis using a Leica SP8 confocal microscope with the HC PL APO CS2 63x / 1.30 NA 391 
glycerol objective, worms were mounted onto slides with 2% agarose pads using 2 µM levamisole for 392 
anaesthesia. Worms were examined using the Leica HyD hybrid detector. The tag mEOS2 was detected 393 
using 506nm as excitation and an emission range from 508-525nm for green fluorescence and 571nm as 394 
excitation and an emission range from 573-602nm for red fluorescence. 3D reconstructions were 395 
performed using the Leica Application Suite (LAS X). For X34 imaging, X34 was excited with a 405nm laser 396 
and detected with an emission window between 470-520nm and RHO-1::tagRFP using 555nm as 397 
excitation and an emission range from 565nm-620nm. For muscle structure imaging, phalloidin was 398 
visualized by excitation at 488nm and with an emission window between 506-551nm and KIN-399 
19::tagRFP, RHO-1::tagRFP and tagRFP were visualized by excitation at 555nm and with an emission 400 
window between 560-650nm.   401 
20 
 
FRAP analysis was performed as previously described (David et al., 2010) using the Leica SP8 confocal 402 
microscope PMT detector. Relative fluorescence intensity (RFI) was analysed as described previously 403 
following the equation RFI = (Tt/Ct)/(T0/C0), where T0 is the intensity in the region of interest (ROI) 404 
before photobleaching; Tt, the intensity in the ROI at a defined time after photobleaching; C0, the 405 
intensity in the non-bleached part of the puncta before photobleaching; and Ct, the intensity in the non-406 
bleached part of the puncta after bleaching (Brignull, Morley, Garcia, & Morimoto, 2006). 407 
 408 
Fluorescence lifetime imaging in vivo: 409 
For fluorescence lifetime imaging, transgenic C. elegans were mounted on microscope slides with 2.5% 410 
agarose pads using 25 mM NaN3 as anaesthetic. All samples were assayed on a modified confocal-based 411 
platform (Olympus FV300-IX70) equipped with a 60x oil objective (PLAPON 60XOSC2 1.4NA, Olympus, 412 
Germany) and integrated with time-correlated single photon counting (TCSPC) FLIM implementation. A 413 
pulsed supercontinuum (WL-SC-400-15, Fianium Ltd., UK) at 40MHz repetition rate served as the 414 
excitation source. YFP was excited at 510nm using a tuneable filter (AOTFnC-400.650, Quanta Tech, New 415 
York, USA). The excitation light was filtered with FF03-510/20 and the fluorescence emission was filtered 416 
with FF01-542/27 (both bandpass filters from Semrock Inc., New York, USA) before reaching the 417 
photomultiplier tube (PMC-100, Becker & Hickl GmBH, Berlin, Germany). Photons were recorded by a 418 
SPC-830 (Becker and Hickl GmBH, Germany) module that permits sorting photons from each pixel into a 419 
histogram according to the photon arrival times. Photons were acquired for two minutes to make a 420 
single 256 X 256 FLIM image and photobleaching was verified to be negligible during this time. Photon 421 
count rates were always kept below 1% of the laser repetition rate to avoid pulse pileup. All raw FLIM 422 
images were fitted with a single exponential decay function using FLIMfit (Warren et al., 2013) and 423 
exported to MATLAB (Mathworks, Inc., Natick, Massachusetts, USA) to obtain an intensity weighted 424 
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lifetime average for each image. Statistical analysis was carried out using two-way ANOVA followed by 425 
Sidak’s multiple comparisons test in Graphpad Prism software (La Jolla, California, USA).  426 
 427 
X34 staining: 428 
Worms were incubated in 1 mM X-34 in 10 mM Tris-HCl pH 8 for two hours, gently shaking at room 429 
temperature as previously described (Link et al., 2001). Worms were then transferred to bacteria seeded 430 
NGM plates to destain overnight before confocal imaging.  431 
 432 
Pharyngeal pumping analysis: 433 
Electrical activity of the pharyngeal pumping was measured using the NemaMetrix ScreenChip System 434 
(NemaMetrix, Eugene OR). To record the electrical activity of pharynx pumping, the NemaMetrix 435 
ScreenChip System (NemaMetrix, Eugene OR) was used. The entire setup is housed in a laboratory that 436 
maintained a temperature of approximately 21°. Baseline noise was typically between 5 and 25 µV.  437 
For each experiment, 50 worms were picked in 1.5 ml of M9 + 0.01% Triton and washed 3 times via low-438 
speed centrifugation. Worms were resuspended in 1.5 ml M9 + 0.01% Triton + 10 µM 5-439 
Hydroxytryptamine creatinine sulfate complex (Serotonin creatinine sulfate monohydrate) (Sigma, 440 
H7752) and incubated for 20 minutes. The ScreenChip system was placed on a stereoscope and loaded 441 
with a fresh screen chip. The screen chip was then vacuum-filled with M9 + 0.01% Triton +10 µM 5-442 
Hydroxytryptamine creatinine sulfate complex and the NemAquire software initiated for baseline noise 443 
checking. The animals were loaded into the recording channel of the screen chip via vacuum. After 444 
loading each animal, we waited at least 30 seconds or until the pumping became regular before starting 445 
to record. Each animal was recorded for approximately 2 minutes regardless of whether pumping activity 446 
was observed or not. Between 20-40 animals were recorded for each condition.  447 
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The recordings were analysed by NemAnalysis v0.2 software using the “Brute Force” optimization 448 
method. The ideal settings were chosen automatically from all combinations of the bounds settings 449 
(Minimum SNR from 1.4 (low) to 2.0 (high), with a Step size of 0.1; Highpass Cutoff from 10 (low) to 20 450 
(high), with a Step size of 5) and applied to produce the analysis results. Data was exported into Excel for 451 
statistical analysis. The student’s t test was used for statistical analysis. 452 
 453 
Thrashing analysis: 454 
To quantify movement in terms of body-bends-per-second, movies of worms swimming in liquid were 455 
acquired with high frame rates (15 frames per second) using a high-resolution monochrome camera (JAI 456 
BM-500 GE, Stemmer imaging GmbH, Puchheim, Germany). For each condition, around 40 animals were 457 
filmed (see Supplementary figure 1 for exact numbers). Worms were picked from cultivation plate and 458 
allowed to swim in a small plastic petri dish filled with M9 + 0.01% Triton. Petri dish containing worms 459 
was placed on a transparent platform and illuminated from bottom up with a flat backlight (CCS TH-460 
211/200-RD, Stemmer imaging GmbH, Puchheim, Germany) to achieve homogeneous, high contrast 461 
lighting. The entire setup is housed in a laboratory that maintained a temperature of approximately 21°. 462 
Movies were taken 10 minutes after placing the animals in the liquid. Five consecutive 30-second movies 463 
were made for each group of worms. The movies were then analysed using the ImageJ wrMTrck plugin 464 
(Nussbaum-Krammer, Neto, Brielmann, Pedersen, & Morimoto, 2015). The wrMTrck plugin tracked 465 
individual worms in the movies and counted the numbers of body-bends. The input values of 466 
wrMTrck_Batch are detailed in Supplementary file 3. Mann-Whitney test was used for statistical analysis 467 
(GraphPad Prism 7). 468 
 469 
Analysis of muscle structure: 470 
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To analyse the muscle structures in the presence of aggregates, worms were collected at day 4 (for body-471 
wall muscle KIN-19::tagRFP strain CF3649 and tagRFP control strain CF3650) and at day 2 (for pharyngeal 472 
RHO-1::tagrfp strain DCD13 and tagRFP control strain CF3317) and fixed in 4% PFA for 10 minutes at 473 
room temperature (RT). Worms were stained with phalloidin to visualize F-actin following a modified 474 
protocol by Karady et al. (Karady et al., 2013). Briefly, worms were washed in phosphate buffered saline 475 
(PBS), incubated for 30 minutes in PBS with  2% Tween and reduced for 30 minutes in Tris-Triton β-476 
mercaptoethanol solution (5% β-mercaptoethanol, 1% triton X-100, 130mM Tris pH 6.8). After washing 477 
with PBS, worms were stained with phalloidin (1:50 in PBS, 0.5% triton X-100; Phalloidin-iFluor™ 488 478 
conjugate from AAT Bioquest), washed and mounted on slides for confocal imaging.  479 
Image analysis of muscle struture was performed in a blind fashion. The body-wall muscle structure was 480 
considered normal when the actin filaments are smooth and tightly arranged with no empty space 481 
between, modest defective when some of the filaments were slightly distorted or less densely packed. 482 
Finally, body-wall muscles were considered severe defective when the filaments appeared significantly 483 
thinner or highly wrinkled, or with large empty space between. The pharyngeal muscle structure was 484 
considered severely defective when the actin filament structure showed large holes. 485 
 486 
Plasmid generation for RHO-1 recombinant expression: 487 
C. elegans RHO-1 cDNA was cloned into pET32a expression vector using restriction sites BamHI and 488 
HindIII (NEB, UK). The open reading frame encoded the RHO-1 fusion protein comprising of a thioredoxin 489 
protein, 6xHis tag and the Tobacco etch virus (TEV) cleavage recognition site with the sequence 490 
ENLYFQA, where TEV cleaves between Q and A, which was also the N-terminal residue of the Rho-1 491 
protein sequence, followed by the RHO-1 protein. The plasmid was confirmed by DNA sequencing 492 
(Source Bioscience, Cambridge, UK). 493 
 494 
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Expression and Isolation of Recombinant RHO-1 from Inclusion Bodies: 495 
Reagents were purchased from Sigma-Aldrich, UK unless stated. BL21 DE3 STAR™ E. coli (Thermo Fisher 496 
Scientific, USA) were transformed with pET32a:RHO-1. 3 L cultures of E. coli in Lysogeny Broth containing 497 
carbenicillin (100 ug/mL) were grown at 37°C at 250 rpm and induced for expression of the RHO-1 fusion 498 
protein with 1 mM isopropyl-β-thiogalactopyranoside (IPTG) for four hours. E. coli were pelleted by 499 
centrifuge at 8000 x g for 15 minutes before being washed by resuspension in PBS with 1% Triton X-110 500 
and 1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and centrifuged again. The pelleted E. coli 501 
were either stored at -20°C until further use or lysed straight away. The RHO-1 fusion protein forms in 502 
inclusion bodies. To release the inclusion bodies, the E. coli were resuspended in 20 mL of lysis buffer per 503 
1 L of culture (50 mM Tris, 500 mM NaCl, 5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride (PMSF), 504 
protease inhibitor tablets (cOmplete™, Mini EDTA-free, Roche), 1% Triton X-110, 1 mM TCEP, pH 8 at 505 
4°C) and sonicated on ice using three rounds of 30 s on and 30 s off 70% sonication power. The 506 
suspension was centrifuged at 10,000 x g for 10 minutes at 4°C. The pellet containing RHO-1 inclusion 507 
bodies was resuspended in 30 mL per 1 L culture of wash buffer 1 (Lysis buffer + 2 M urea, pH 8 at 4°C). 508 
The inclusion bodies were sonicated for four rounds of 10 s on, 20 s off and centrifuged at 10,000 x g for 509 
10 minutes at 4°C, this wash was then repeated again. Wash number 3 and 4 used the same sonication 510 
and centrifuge parameters, but pellets were washed with wash buffer 2 (Lysis buffer, 2 M urea, 1 mM 511 
TCEP, without Triton-110 or protease inhibitors). The final pellet became paler and more chalk-like. 512 
These wash steps are important to lead to a purer final RHO-1 protein. The inclusion bodies were then 513 
solublised in solublising buffer using 10 mL per 1 L of culture for 1 hour using a magnetic stirrer (50 mM 514 
Tris, 500 mM NaCl, 5 mM MgCl2, 6 M guanidinium hydrochloride (GuHCl), 1 mM TCEP, (6 M Urea can 515 
also be used in place of GuHCl, but GuHCl gives a slightly higher final protein yield)). Insoluble material 516 
was removed by centrifuge at 16,000 x g for 10 minutes at room temperature (RT). 517 
 518 
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Purification of Recombinant RHO-1: 519 
The RHO-1 fusion protein was purified using two linked-together 1 mL HisTrap Crude FF columns on an 520 
ÄKTA Pure (GE Healthcare, Sweden). The columns were equilibrated with solublising buffer before 10 mL 521 
of protein was loaded onto the column by the sample pump. The columns were washed in wash buffer 522 
(50 mM Tris, 500 mM NaCl, 5 mM MgCl2, 6 M Urea, 20 mM imidazole) before being eluted against a 523 
linear gradient of elution buffer (50 mM Tris, 500 mM NaCl, 5 mM MgCl2, 6 M Urea, 500 mM imidazole) 524 
over 16 column volumes of a 1 x 1 mL column, i.e. 16 mL. Multiple purification runs were performed until 525 
all RHO-1 fusion protein was purified. Fractions from all runs containing the RHO-1 fusion protein were 526 
pooled and dialysed overnight in 2 L stabilising buffer modified from ((Healthcare; Nelson, Lee, & 527 
Fremont, 2014; Thomson, Olson, Jackson, & Schrader, 2012) (50 mM Tris, 250 mM NaCl, 100 mM 528 
arginine, 5 mM reduced glutathione, 0.5 mM oxidised glutathione, 5 mM MgCl2, 5 µM guanosine 5’-529 
diphosphate (GDP) (Generon, UK) pH 7.2). The RHO-1 fusion protein was then concentrated to 1 mL per 530 
1 L culture using Spectra/Gel Absorbent (Spectrum Labs, USA) through a 10 kDa MWCO Slide-A-Lyzer™ 531 
dialysis cassette (Thermo Fisher Scientific). The RHO-1 fusion protein was then incubated overnight with 532 
recombinant TEV protease to cleave the RHO-1 from the fusion tag in a 1:50 ration of TEV to RHO-1 533 
fusion protein based on absorbance at 280 nm. Recombinant TEV was produced by Dr Marielle Wälti 534 
using methods from (Tropea, Cherry, & Waugh, 2009). The cleaved RHO-1 was separated from the fusion 535 
tag and TEV protein by purification using the two linked-together 1 mL HisTrap Crude FF columns on an 536 
ÄKTA Pure. The columns were equilibrated in stabilising buffer and 1 mL of the protein loaded onto the 537 
columns by injection. Cleaved RHO-1 was eluted in stabilisation buffer during the column wash. The 538 
fusion tag and the His-tagged TEV were retained on the column and eluted with 100% elution buffer over 539 
10 CV (stabilisation buffer with 500 mM imidazole). Protein concentration was monitored throughout 540 
purification using the extinction coefficient 0.862 M-1 cm-1 for the fusion protein, 0.849 M-1 cm-1 for the 541 
refolded fusion protein and 0.875 M-1 cm-1 for the cleaved refolded RHO-1 protein. Quantitative analysis 542 
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of protein purity was performed in FIJI image analysis software (Schindelin et al., 2012) by profiling 543 
protein band intensity of the stained gel mass spectrometry confirmed the purification of RHO-1. To 544 
note, RHO-1 precipitated in NaP, Tris, NaCl buffers. RHO-1 protein mass was confirmed by mass 545 
spectrometry.  546 
 547 
Fibrillisation of RHO-1 and analysis by Transmission Electron Microscopy (TEM): 548 
RHO-1 was fibrillised by incubating 20 µM in stabilising buffer during a Thioflavin-T (ThT) based-assay 549 
with 10 µM ThT (AbCam, UK)  in non-binding, clear bottom, black 96-well plate (PN 655906 Greiner Bio-550 
One GmbH, Germany). The plate was incubated at 37°C with constant shaking at 300 rpm for 7 days. 551 
RHO-1 was taken from the wells in the microplate for imaging by TEM. All samples also contained 0.05% 552 
NaN3 to prevent bacterial growth. Samples were incubated in an oven rotating at maximum speed (UVP 553 
HB-1000 Hybridizer, Fisher Scientific) at 37°C for five weeks. 554 
Fibrillised RHO-1 samples were centrifuged for 20 minutes at 21,000 x g and the supernatant removed 555 
leaving 10 µL of sample. Each 10 µL sample was incubated on a glow-discharged copper grid for 1 556 
minute. Excess liquid was blotted off and the grid washed in twice in dH2O for 15 seconds. 2% uranyl 557 
acetate was used to negatively stain the samples for 30 s before imaging on the Tecnai G2 80-200kv TEM 558 
at the Cambridge Advanced Imaging Centre. 559 
 560 
Preparation and analysis of worm lysates for fibrils by TEM: 561 
C. elegans DCD146 expressing RHO-1::Venus, DCD242 expressing KIN-19::HisAvi and DCD243 expressing 562 
RHO-1::HisAvi were grown to confluency on high growth medium plates and bleached to obtain a 563 
synchronized population of worms as previously described (Sulston, 1988). L1s were transferred into a 564 
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liquid culture with complete S basal supplemented with OP50-1 (OP50 with Streptomycin resistance) and 565 
grown at 20°C or 25°C (to induce sterility of DCD242 and DCD243) as previously described (Groh, Buhler, 566 
et al., 2017; Groh, Gallotta, et al., 2017). At day 1 of adulthood (DCD146) or at day 7 of adulthood 567 
(DCD242 and DCD243), worms were allowed to sediment in a separation funnel and washed with cold 568 
M9. The worm pellet was resuspended in PBS with 2x protease inhibitor tablets (cOmplete™, Mini EDTA-569 
free, Roche) and frozen in liquid nitrogen. For TEM with RHO-1::Venus, frozen worms were resuspended 570 
in radioimmunoprecipitation assay (RIPA) buffer with protease inhibitor tablets and lysed by 20-25 571 
passages through a cell homogeniser (Isobiotec, Germany) using a tungsten carbide ball with 16 µm 572 
clearance. Cuticle fragments and unlysed worms were removed by centrifugation for 5 min at 835 g and 573 
4 °C. After careful removal of the supernatant, the insoluble fraction was collected by centrifugation for 574 
30 min at 21,000 g and 4 °C. The supernatant was removed and the pellet was resuspended in PBS with 575 
protease inhibitor tablets by homogenising with a needle (27G, Sterican). To perform TEM with fibrils 576 
isolated by affinity, we pulled down His-tagged RHO-1 and KIN-19 by nickel beads. For this, 250 µL worm 577 
extract was added to 250 µL RIPA buffer (Invitrogen) with protease inhibitors and sonicated for 10s 578 
twice. Cuticle fragments and unlysed worms were removed by centrifugation for 1 minute at 800 x g. The 579 
supernatant was removed and centrifuged at 21 k x g for 20 minutes. The pellet was resuspended in 250 580 
µL PBS with protease inhibitors and passed through a 30 G needle three times. 20 µL of precharged 581 
Nickel Sepharose 6 Fast Flow beads taken from a HisTrap FF Crude column (GE Healthcare, Uppsala, 582 
Sweden) were incubated with the resuspended pellet overnight at 4°C on a fixed speed rotator at 20 rpm 583 
(SB2, Stuart, Staffordshire, UK). To separate the beads from unbound proteins the tubes were 584 
centrifuged at 800 x g for 1 min and the supernatant removed. 60 µL of 500 mM imidazole in PBS pH 8 585 
was added to the beads and incubated overnight at 4°C on a fixed speed rotator at 20 rpm. To isolate 586 
eluted fibrils the tubes were centrifuged at 800 x g for 1 min and the supernatant containing the fibrils 587 
was used for TEM experiments. 10 µL sample was applied to a carbon coated grid, and 2% uranyl acetate 588 
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was used for negative staining. Imaging was performed on the Tecnai G2 80-200kv TEM at the 589 
Cambridge Advanced Imaging Centre. 590 
 591 
Preparation and analysis of worm lysates for fibrils by SIM: 592 
Nunc® Lab-Tek® II Chamber Slide™ (Sigma, Dorset, UK) were coated for 30 min with 0.01 % poly-L-Lysine 593 
(P4707, Sigma) before incubation for one hour with either nickel bead extracted fibrils or resuspended 594 
worm pellets prepared as described above. RHO-1::tagRFP expressing transgenics (DCD13) and fem-1(-) 595 
mutants (CF2137; the non-aggregated control worm) extracts were incubated with 50 µM thioflavin T 596 
(ThT) (#ab120751, abcam, UK) for one hour and washed three times in PBS before imaging. To visualize 597 
amyloids from worm extracts, we used our custom-built SIM providing a spatial resolution approaching 598 
90 nm at frame rates reaching 22 Hz (Young et al., 2016). Hardware control and image reconstruction 599 
were performed with software written in LabView and Matlab (Strohl & Kaminski, 2015). For 600 
visualization, ImageJ was used.  601 
 602 
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Figure legends 814 
Figure 1: Newly synthesized KIN-19 rapidly transitions into aggregates in aged animals 815 
(A, B) Following photoconversion at day 5 in the pharynx or in the body-wall muscle, the number of 816 
animals with newly synthesized green-emitting non-converted KIN-19::mEOS2 aggregates doubles over 817 
24 hours. Conversely levels of red-emitting converted aggregates slowly declines. Blocking translation 818 
with cycloheximide (CHX) prevents new aggregate formation (B). Aggregation is evaluated in Pkin-819 
19::KIN-19::mEOS2 and Pmyo-3::KIN-19::mEOS2 transgenic animals on the basis of the fluorescence 820 
intensity in puncta, representing aggregation (see methods). Quantification was done in the same 821 
population of C. elegans before conversion (BC), after conversion (AC), 24h after conversion and 48h 822 
after conversion. Fisher’s exact test comparing low versus medium + high aggregation levels to after 823 
conversion: *p < 0.05, **p < 0.01, ****p < 0.0001. Fisher’s exact test comparing low + medium versus 824 
high aggregation levels to after conversion: °°p < 0.01. See source data including independent biological 825 
repeat in supplementary file 1.  826 
(C) 24 hours after photoconversion at day 7, newly synthesized KIN-19::mEOS2 (green emitting) forms 827 
new aggregates and associates around older aggregates (red emitting). 3D reconstruction in the 828 
pharyngeal anterior bulb region. Arrow heads highlight large new aggregates formed independently of 829 
previous aggregates. Scale bar 2 μm. 830 
 831 
Figure supplement 1 (related to Figure 1): Newly synthesized KIN-19 and RHO-1 rapidly transitions into 832 
aggregates in young animals 833 
(A) KIN-19::mEOS2 puncta visible in the body wall muscle contain immobile protein, demonstrated by 834 
lack of fluorescent recovery after photobleaching (FRAP) after 5 minutes. Area bleached enlarged in 835 
caption. Scale bar 2 μm.  836 
35 
 
(B) KIN-19::mEOS2 puncta visible in the pharynx contain immobile protein, demonstrated by FRAP after 8 837 
minutes. Area bleached enlarged in caption. Scale bar 2 μm. 838 
(C) FRAP analysis of KIN-19::mEOS2 puncta present in aged worms. Quantification of relative 839 
fluorescence intensity (RFI) over time. Number of animals = 4, puncta evaluated = 6, mean ± SD is 840 
represented. See source data in supplementary file 1. 841 
(D) FRAP analysis of mEOS2 puncta/areas of fluorescence present in aged worms. Number of animals = 3, 842 
puncta evaluated = 6, mean ± SD is represented. Only a few puncta are present in a population of 843 
animals overexpressing Pkin-19::mEOS2 (one in 80 transgenics at day 9 had more than 10 puncta in 844 
anterior bulb). 845 
(E) In young animals, aggregates are formed by newly synthesized KIN-19 and inhibition of translation (by 846 
cycloheximide (CHX)) reduces new aggregate formation. Aggregation is evaluated in Pkin-19::KIN-847 
19::mEOS2 transgenic animals on the basis of the fluorescence intensity in puncta, representing 848 
aggregation (see methods). Quantification was done in the same population of C. elegans before 849 
conversion (BC) at day 2, after conversion (AC), 24h after conversion and 48h after conversion. Fisher’s 850 
exact test comparing low versus medium + high aggregation levels to after conversion: *p < 0.05, **p < 851 
0.01, ****p < 0.0001. See source data in supplementary file 1.  852 
  853 
(F) RHO-1::mEOS2 aggregates strongly already at day 1 and forms new aggregates (green) 24 h after 854 
photoconversion and associates with older aggregates (red). Scale bar 15 μm, 7 μm in zoom. 855 
 856 
Figure 2: Drop in fluorescence lifetime reveals amyloid-like structure of KIN-19 and RHO-1 aggregates 857 
in live C. elegans.  858 
36 
 
(A) Representative intensity-weighted FLIM images of Venus only (control), RHO-1::Venus and KIN-859 
19::Venus worms. Scale = 25 μm. Inset shows zoomed-in images (intensity and FLIM) of the anterior bulb 860 
for Venus only, RHO-1::Venus and KIN-19::Venus worms at day 12. Scale = 25 μm. 861 
(B) Scatter plot shows a drop in the intensity-weighted fluorescence lifetime averages in adult worms 862 
expressing RHO-1::Venus and KIN-19::Venus compared to worms expressing Venus only (control) in the 863 
pharynx. n = 7-10, 2 independent biological repeats. Data is shown as mean lifetime +/- SEM and the 864 
statistical analysis was performed using two-way ANOVA with Sidak´s multiple comparisons test: ** 865 
p<0.01, **** p<0.0001. See source data in supplementary file 1. 866 
(C) Normalised histograms of intensity-weighted fluorescence lifetimes for RHO-1::Venus and KIN-867 
19::Venus show a population shift towards lower lifetimes compared to Venus only (control) worms. The 868 
histograms contain information from all pixels of all images acquired for each condition.  869 
 870 
Figure supplement 2 (related to Figure 2): Fibrillation propensity calculate by ZipperDB 871 
(A) Fibrillation propensity profile for KIN-19 872 
(B) Fibrillation propensity profile for RHO-1 873 
Table inlet shows hexapeptides with Composite scores below -45.  874 
ZipperDB: https://services.mbi.ucla.edu/zipperdb/ 875 
 876 
Figure supplement 3 (related to Figure 2): Aggregation with age of RHO-1::Venus and KIN-19::Venus 877 
(A) Increased pharyngeal KIN-19 aggregation with age in animals expressing Pkin-19::KIN-19::Venus. 878 
Panel reproduced from https://doi.org/10.1016/j.celrep.2016.12.033. 879 
(B) Increased pharyngeal RHO-1 aggregation with age in animals expressing Pmyo-2::RHO-1::Venus. 880 
37 
 
Numbers of worms indicated in the bars. Significance calculated low + medium versus high aggregation 881 
levels compared to day 2 of adulthood; Fisher’s exact test: ****p< 0.0001. See source data in 882 
supplementary file 1. 883 
(C) RHO-1::Venus puncta visible in the pharynx contain immobile protein, demonstrated by absence of 884 
fluorescence recovery after 4 minutes. Scale bar 2 μm. 885 
(D) RHO-1::Venus aggregates are highly immobile. Table summarizes FRAP experiments carried out at 886 
different ages. 887 
(E) FRAP analysis of RHO-1::Venus puncta present in aged worms compared to Venus alone. 888 
Quantification of RFI over time. Number of animals = 5, puncta evaluated = 6, mean ± SD is represented. 889 
See source data in supplementary file 1. 890 
  891 
Figure supplement 4 (related to Figure 2): Staining of RHO-1::tagRFP with Congo red derivative X34 892 
(A) Representative fluorescence decay curves, lifetime fits (with associated chi2 values) and fit residuals 893 
for Venus only (control), RHO-1::Venus and KIN-19::Venus adult worms at day 12. The black trace 894 
represents the instrument response function (IRF). 895 
(B) Drop in fluorescence lifetime upon RHO-1::tagRFP aggregation. Scatter plot showing the intensity-896 
weighted mean fluorescence lifetime values of day 1 adult worms expressing RHO-1::tagRFP in the 897 
pharynx compared to worms expressing tagRFP only. n = 7-8, 2 independent biological repeats 898 
combined. t-test with Welch's correction for unequal standard deviations: **** p<0.0001. 899 
See source data in supplementary file 1. 900 
(C) RHO-1 aggregates are stained by Congo red derivative X34. Day 2 old animals expressing Pmyo-901 
2::RHO-1::tagRFP. Scale bar 30 μm. Zoom scale bar 15 μm. 902 
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(D) Absence of X34 staining in wild-type pharynx. Day 3 old wild-type animals (N2). Scale bar 30 μm. 903 
Zoom scale bar 15 μm. 904 
(E) RHO-1::tagRFP fluorescence does not interfer with X34 fluorescence as demonstrated by eliminating 905 
tagRFP fluorescence by bleaching (in white square). Scale bar 3 μm. 906 
 907 
Figure supplement 5 (related to Figure 2): Recombinant RHO-1 forms amyloid-like fibrils in vitro and in 908 
vivo 909 
 (A) Purification steps of recombinant RHO-1 analyzed by SDS-PAGE gel electrophoresis and Coomassie 910 
staining. The RHO-1 fusion protein consisting of the thioredoxin protein, His tag and Tobacco etch virus 911 
(TEV) cleavage recognition site was purified on a Crude FF column and eluted with imidazole. It ran 912 
slightly quicker than the expected 40 kDa predicted size (lane 1). The fusion protein was incubated with 913 
recombinant TEV protease overnight in a 1:50 ratio (lane 2). The cleaved RHO-1 protein did not bind to 914 
the Crude FF column and eluted in the flow through (lane 3). The TEV protease which has a 6xHis tag and 915 
the remaining uncleaved fusion protein were eluted from the column with imidazole (lane 4). 916 
(B) Matrix Assisted Laser Desorption/Ionization (MADLI) mass spectrometry of purified RHO-1. 917 
Performed by the Proteomics Facility, Biochemistry Department, University of Cambridge. 918 
(C) Negative-stain transmission electron micrographs of fibrillised RHO-1. TEM of RHO-1 negatively 919 
stained using 2% uranyl acetate. RHO-1 was incubated for 1 week in a ThT assay to fibrillise. Scale bar = 920 
200 nm.  921 
(D) Negative-stain transmission electron micrographs of pmyo-2::RHO-1::Venus worm lysates, day 1. TEM 922 
of RHO-1 fibrils negatively stained using 2% uranyl acetate. Scale bar = 200 nm.  923 
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(E) Negative-stain transmission electron micrographs of RHO-1::HisAvi and KIN-19::HisAvi purified from 924 
worms lysates with nickel beads, day 7. Scale bar = 200 nm.  925 
 926 
Figure supplement 6 (related to Figure 2): Structured illumination microscopy reveals that RHO-1 927 
forms ThT positive fibril structures in vivo 928 
(A) Left image: SIM image of RHO-1 fibrils isolated by affinity purification from transgenics expressing 929 
RHO-1::HisAvi at day 7 and labelled using the amyloid dye ThT. Right image: Zoomed in image of left 930 
image highlighting the fibril bundles formed by RHO-1 in vivo. Circled in red, single fibrils; in green, fibril 931 
bundles and in blue, fibril clusters. Scale bars:  5 and 1 µm, respectively. (B) Two colour SIM images of 932 
RHO-1 fibrils extracted from transgenics expressing RHO-1::tagRFP (day 2). Fibrils were stained with ThT 933 
prior to imaging. Left image: SIM image of ThT positive RHO-1::tagRFP fibrils. Central image: SIM image 934 
of the same fibril as shown in left but upon tagRFP excitation. Right image: Overlay of ThT and tagRFP 935 
channels displays co-localization of ThT and RFP of extracted RHO-1::tagRFP fibrils. Lower panel: imaging 936 
of control extracts from young animals (sterile fem-1(-) mutants). Scale bar: 1 µm.  937 
 938 
Figure 3: Age-dependent protein aggregation impairs pharyngeal and body-wall muscle function. 939 
(A) Aged animals with high levels of pharyngeal KIN-19 aggregation have reduced pharyngeal pumping. 940 
N= 23-28 animals analyzed per group. T-test: p< 0.0001.  941 
(B) Aged animals with high levels of KIN-19 aggregation in the body-wall muscle display reduced 942 
thrashing. Mean body bends per seconds are set to 100% in animals with low aggregation. Mann-943 
Whitney test: p< 0.0001.  944 
(C) Young animals with RHO-1 aggregation in pharynx have impaired pharyngeal pumping. N= 26-27 945 
animals analyzed per group. T-test: p< 0.0001.  946 
40 
 
(D) Overexpression of RHO-1 without aggregation in the body-wall muscles does not influence thrashing. 947 
Mean body bends per seconds are set to 100% in Punc-54::yfp transgenic animals. Mann-Whitney test: 948 
non-significant.  949 
SEM represented, independent biological repeats in supplementary file 2 and source data in 950 
supplementary file 1. 951 
 952 
Figure supplement 7 (related to Figure 3): Markers for age-dependent protein aggregation 953 
(A) Increased pharyngeal KIN-19 aggregation with age in animals expressing Pkin-19::KIN-19::tagRFP. 954 
(B) Increased body-wall muscle KIN-19 aggregation with age in animals expressing Pmyo-3::KIN-955 
19::tagRFP. 956 
(C) Increased pharyngeal RHO-1 aggregation with age in animals expressing Pmyo-2::RHO-1::tagRFP. 957 
Already young adults display abundant RHO-1 aggregation. 958 
(D) Absence of RHO-1 aggregation in the majority of animals expressing Punc-54::RHO-1::Venus. 959 
Numbers of worms indicated in the bars. Significance calculated low + medium versus high aggregation 960 
levels compared to day 2 of adulthood; Fisher’s exact test: **p< 0.01, ***p< 0.001, ****p< 0.0001. See 961 
source data in supplementary file 1. 962 
(E) RHO-1::tagRFP aggregates abundantly at day 2 compared to KIN-19::tagRFP. Fluorescent micrograph 963 
of the upper body region of animals expressing Pkin-19::KIN-19::tagRFP or Pmyo-2::RHO-1::tagRFP. Days 964 
of adulthood and exposure times displayed under images. Arrow heads highlight animals with high levels 965 
of KIN-19 aggregation in anterior bulb. Scale bar: 100 μm 966 
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(F) KIN-19::tagRFP but not RHO-1::Venus aggregates in body-wall muscle (small puncta). Fluorescent 967 
micrograph of whole animals expressing Punc-54::RHO-1::Venus or Pmyo-3::KIN-19::tagRFP. Head region 968 
on the left. Days of adulthood and exposure times displayed under images. Scale bar: 200 μm. 969 
 970 
Figure supplement 8 (related to Figure 3): KIN-19 aggregation in body-wall muscles impairs thrashing 971 
(A) KIN-19 aggregation in body-wall muscles impairs thrashing.  Mean body bends per seconds are set to 972 
100% in Pmyo-3::tagRFP transgenics. Mann-Whitney test: ****p<0.0001 973 
(B) No effect on pumping detected in animals with mixed levels of KIN-19::tagRFP aggregation. N= 29-39 974 
animals analyzed per group. T-test: non-significant.  975 
(C) Fluorescent tagRFP does not affect pharyngeal pumping in young animals. N= 26-27 animals analyzed 976 
per group. T-test: non-significant.  977 
(D) Fluorescent tagRFP does not affect pharyngeal pumping in aged animals. N= 23-26 animals analyzed 978 
per group. T-test: non-significant.  979 
SEM represented, independent biological repeats in supplementary file 2 and source data in 980 
supplementary file 1. 981 
 982 
Figure supplement 9 (related to Figure 3): KIN-19 and RHO-1 aggregation impacts muscle structure 983 
(A, B) Animals with KIN-19 aggregates show defective body-wall muscle structure at day 4. (A)  984 
Representative single-plane image showing wrinkled, thinner and faded actin filaments in the presence 985 
of KIN-19 aggregates. Top panel: F-actin staining with phalloidin (green). Bottom panel: Merged image 986 
with KIN-19 aggregates (magenta). Scale bar 30 µm. (B) Quantification of the decline in body-wall muscle 987 
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structure with KIN-19 aggregation. Fisher’s exact test: ****p< 0.0001. See source data in supplementary 988 
file 1. 989 
(C, D) Animals with RHO-1 aggregates show defective pharyngeal muscle structure at day 2. (C)  990 
Representative single-plane image showing holes in the actin filaments in the presence of RHO-1 991 
aggregates. Top: merged view of pharynx (RHO-1::tagRFP, tagRFP in magenta and F-actin staining with 992 
phalloidin in green); Bottom: zoom into boxed area. Scale bar: 15 µm, zoom: 3 µm. (D) Quantification of 993 
defective pharyngeal muscle structure with RHO-1 aggregation. Fisher’s exact test: ****p< 0.0001. See 994 
source data in supplementary file 1. 995 
 996 
Supplementary file 1: source data 997 
Supplementary file 2: Pharyngeal pumping and thrashing repeats 998 
Supplementary file 3: parameters for thrashing analysis 999 
 1000 
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